Ideaya IPO: At An Early Stage Of Development, But Google(NASDAQ:GOOG) Is A Shareholder #Source_ProspectusAugust 4, 2019
Besides, the company’s lead product candidate, which was acquired from Novartis ( NVS ), showed several adverse events in the Phase 1 trial.
The images below offer further details about the results obtained:
The image below offers further information on the type of adverse events reported:
IDYA has several biomarkers which should help the company target large market size.
Bear in mind that in 2017, cash and short-term securities amounted to $13 million.
Bear in mind that IDYA should increase its costs as more patients are tested in Phase 2 and Phase 3.
The company competes with many small companies.
As shown in the image below, in 2014 and 2015, the enterprise value of Agios is approximated to $1 billion – $4 billion:
Besides, IDYA’s valuation should go above $1 billion as IDYA’s pipeline does not include product candidates at a late stage of development.
Additionally, IDYA has many biomarkers, and it’s targeting a significant market opportunity.
As I picked up my morning coffee, I scoped out the place for possible prey. A new cock to suck from a suitable guy was on my breakfast menu. I made eye contact with a good-looking 30-something but quickly realized that he was a former conquest. As he approached to say hello, I raised my hand like a traffic cop and shook my head no. He stopped and retreated, obviously disappointed. I was looking for some fresh meat. However, I was so horny and hungry for cock and hot cum that if nothing new was to my liking I would go back to the 30-something, but I had to act quickly, as always.